


Tenofovir Alafenamide Reduces HTLV-1c Transmission in a Novel Humanised Mouse Model of Infection


James Cooney
Pellegrini Laboratory
The Walter and Eliza Hall Institute

Mastery of Disease Through Discovery


Chronic HTLV-1c infection can be established in humanised mice




HTLV-1c-infected mice develop high pro-viral load




The HTLV-1c pro-virus is detected in multiple tissues and cellular compartments



HTLV-1c causes leukocytosis in infected animals




Mock-infected




HTLV-1c-infected



HTLV-1c infected cells have flower/'lobed-like' nuclei




Humanised mice PBMC




Patient PBMC



HTLV-1c infected animals develop splenomegaly




HTLV-1c infected animals have immune-cell infiltration in the liver




Mock-infected liver (H&E)

HTLV-1c infected liver (H&E)


HTLV-1c causes leukocytosis in infected animals




CD4⁺ and CD8⁺ T-cell expansion in HTLV-1c infected mice



HTLV-1c-infected CD4⁺ T-cells have a mature phenotype and express CD25




The proportion of T-regulatory cells decreases in HTLV-1c infected mice



***P<0.001

The proportion of T-regulatory cells decreases in HTLV-1c infected mice



Summary

- HTLV-1c-infected humanised mice recapitulate many aspects of human disease.
- An ideal tool to study the efficacy of therapeutic intervention strategies against HTLV-1c.
- Tenofovir alafenamide significantly reduces transmission of HTLV-1c in this model.
- This model aims to generate pre-clinical data to inform clinical trial design.
- Future work will focus on examining the efficacy of therapeutic interventions in established disease.



Acknowledgements

Pellegrini Lab

Marc Pellegrini

Cody Allison

Simon Preston

Melissa Hobbs

Marcel Doerflinger

Damian Purcell

David Yurick

Lloyd Einsiedel

Sara Erickson

Bioservices:

Carolina Alvarado

Merle Dayton

Proteomics lab

Steven Wilcox

FACS lab

Mel LePage



Australian Government
National Health and
Medical Research Council



Australian Centre for
HIV and Hepatitis Virology Research



THE UNIVERSITY OF
MELBOURNE

Disclosure of interest: None to declare.